|
The patient was wearing a pod on the hip/buttocks for between 37 and 48 hours.On (b)(6) 2026, while visiting italy, the patient experienced hyperglycemia with blood glucose reported at 400 mg/dl (22.2 mmol/l) despite multiple correction boluses and minimal food intake.The patient reported increasing ketone levels (approximately 0.4 mmol/l and rising), dizziness, significant weakness, feeling increasingly unwell, and concern that insulin delivery may not have been occurring as expected.The patient reported signs consistent with insulin leakage during wear and reported feeling insulin on the skin.The patient sought medical attention and was treated in the emergency department for approximately 3 hours with intravenous fluids and novorapid insulin.The pod remained in use during medical treatment.After returning to the hotel, the patient removed the pod and applied a new pod filled with novorapid insulin.Blood glucose and ketone levels subsequently improved, and the reported event resolved.
|
|
The device has not been returned/received to date.If the device is received, a supplemental report will be submitted with the investigation results.We are unable to determine if any product condition could have contributed to the reported event.Lot release records were reviewed, and the product lot met all acceptance criteria.
|